Define the operating boundary
A useful definition names the triggering event, required inputs, governing source, accountable owner, decision or action, exception path, evidence retained, and downstream handoff. Buyers should adapt those elements to their own population, jurisdictions, policies, systems, and control model before writing requirements.
The most important distinction is between a label and an operational capability. A provider may document denial reason and correspondence while depending on customer-supplied policy, licensed content, third-party data, integration partners, manual review, or services. The demonstration should expose those dependencies rather than hiding them behind a completed interface.
What a demonstration should prove
- Begin with representative source records and a named policy, standard, or controlled rule.
- Show the normal path, an ambiguous case, missing data, an exception, an override, and a material source change.
- Identify who can change rules, who can approve or reject, and how accountability is preserved.
- Trace every output back to inputs, versions, timestamps, user actions, and governing evidence.
- Export the resulting record and reconcile it with downstream systems and retained obligations.
Authority and operating context
CMS-0057-F
The rule requires impacted payers to improve prior authorization decision timeframes and denial reasons, publish aggregated prior authorization metrics, and implement FHIR-based Prior Authorization and other interoperability APIs. The prior authorization API provisions addressed by the final rule exclude drugs. It changes prior authorization from a mainly plan-specific operational process into a federally time-bounded, reportable, and API-enabled workflow for impacted non-drug items and services. It also creates concrete buyer requirements for denial reasons, metrics lineage, and CRD, DTR, and PAS implementation.
CMS-0062-P
The proposal would extend many electronic prior authorization, decision-time, transparency, API, and reporting policies to drugs and would adopt or update FHIR-based standards and implementation specifications for prior authorization transactions. The proposals are not final policy. It could materially reduce the current boundary between medical-service and drug prior authorization regulation while changing standards, response times, and metrics. Buyers must plan for the possibility without treating proposed provisions as current obligations.
NCQA UM Accreditation
NCQA UM Accreditation evaluates organizations that make utilization decisions against a framework for objective, evidence-based, fair, and timely operations. Detailed standards cover clinical information, review processes, timeliness, appeals, and related controls. Accreditation changes the evaluation from feature presence to controlled operation. Technology can support evidence, timelines, reviewer qualification, and audit trails, but the organization—not the software—holds accreditation.
URAC Health UM Accreditation
URAC accredits health utilization-management organizations against standards intended to support effective, transparent, and efficient UM functions, including organizational accountability and consumer protections. URAC status can be relevant evidence about an organization's operating controls, but accreditation scope and expiration must be checked. A technology platform cannot inherit the accreditation of a service organization merely through integration.
Operating domains
Clinical appropriateness and decision integrity
Risk that clinical criteria, benefit rules, extracted evidence, reviewer qualifications, automation, or escalation logic produce inconsistent, unsupported, biased, or clinically inappropriate authorization recommendations or determinations.
Delegation, governance, and accountability
Risk that a health plan cannot demonstrate who owns policy, clinical review, decision authority, notices, appeals, metrics, accreditation, and oversight when work crosses internal teams and delegated organizations.
Denials, appeals, and member rights
Risk that adverse determinations lack specific, understandable reasons; appeal rights and peer review are hard to access; deadlines are missed; or later reversals cannot be analyzed without compromising member protections.
Evidence and comparison limits
Official provider documentation can establish product positioning. Provider confirmation can clarify package or availability. Independent observation requires a disclosed scenario, environment, date, inputs, and reproducible result. None of those sources alone establishes buyer-specific legal, clinical, regulatory, quality, or operational fitness.
Buyer questions
- What exact outcome and evidence should denial reason and correspondence produce?
- Which source, version, and customer facts govern the workflow?
- Which decisions remain human and who is accountable for them?
- What is native, configured, integrated, service-delivered, or planned?
- How does a changed source affect open and historical records?
Recent changes
CMS releases CMS-0062-P for drug prior authorization and interoperability — Pharmacy ePA networks, payers, PBMs, EHRs, pharmacies, clearinghouses, and FHIR infrastructure providers need a scenario plan that preserves the distinction between current obligations and proposed changes.
Initial CMS-0057 prior-authorization metrics become due — Plan-level public disclosures create a new benchmarking input, but files require normalization by entity, population, period, request type, and denominator before comparison.